AMVUTTRA™
AMVUTTRA™ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Administration and Dosage:
AMVUTTRA™ is dosed 4 times per year via subcutaneous injection
Common Side Effects:
The most common adverse reactions that occurred in patients treated with AMVUTTRA were arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).
More information:
Please see full Prescribing Information including Patient Information.
Indication:
AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!
Check our Privacy Practice